Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.85 |
| ▸ | TUBB | P07437 | 4/20 | 0.85 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.85 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.85 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.85 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.85 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.85 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.85 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.85 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.85 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.85 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.85 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.85 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.85 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.81 |
| ▸ | P4HB | P07237 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371281 | 1.00 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL835433 | 1.00 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18389685 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19601281 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14669823 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26212394 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12371283 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL836373 | 0.96 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26553713 | 0.96 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26553718 | 0.96 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-10005836-B2 | Antibody drug conjugates | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20180147295-A1 | Trimaleimide Linkers and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-9982045-B2 | Anti-CDH6 antibody drug conjugates | NOVARTIS AG (CH) | 2018-05-29 | — | — | US | disclosed |
| US-20180141973-A1 | Derivatives of Dolastatin 10 and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180125996-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2018-05-10 | — | — | US | disclosed |
| US-20170224836-A1 | ANTI-CDH6 ANTIBODY DRUG CONJUGATES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-08-10 | — | — | US | disclosed |
| US-20090286258-A1 | ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY | GENENTECH, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7521541-B2 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENETECH INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090068178-A1 | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin | GENENTECH, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | GENENTECH, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147295-A1 | Trimaleimide Linkers and Uses Thereof | TXLNA, TRIM59, NAALAD2 | TUBB4A 885/4885TUBB 356/4885TUBA3C 715/4885 |
| US-20170224836-A1 | ANTI-CDH6 ANTIBODY DRUG CONJUGATES | EPCAM, CD44, CDH1 | TUBB4A 282/4885TUBB 368/4885TUBA3C 302/4885 |
| US-20090068178-A1 | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin | HCLS1, CD47, MCL1 | TUBB4A 397/4885TUBB 550/4885TUBA3C 484/4885 |
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | CTH, LNPEP, CARS1 | TUBB4A 843/4885TUBB 781/4885TUBA3C 393/4885 |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | ERBB2, EGFR, ERBB4 | TUBB4A 1049/4885TUBB 1421/4885TUBA3C 1997/4885 |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | TUBB4A 1814/4885TUBB 1342/4885TUBA3C 1992/4885 |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | CCR7, BCL6, CXCR3 | TUBB4A 746/4885TUBB 607/4885TUBA3C 472/4885 |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | CTH, LNPEP, CARS1 | TUBB4A 843/4885TUBB 781/4885TUBA3C 393/4885 |
| US-20180141973-A1 | Derivatives of Dolastatin 10 and Uses Thereof | PCSK9, DDOST, DHCR7 | TUBB4A 660/4885TUBB 1303/4885TUBA3C 2251/4885 |
| US-10005836-B2 | Antibody drug conjugates | EPCAM, CDH1, CD44 | TUBB4A 270/4885TUBB 316/4885TUBA3C 202/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | TUBB4A 231/4885TUBB 122/4885TUBA3C 345/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | TUBB4A 104/4885TUBB 35/4885TUBA3C 537/4885 |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | ERBB2, EGFR, ERBB4 | TUBB4A 1372/4885TUBB 1593/4885TUBA3C 2748/4885 |
| US-20180125996-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CD44, ABL1 | TUBB4A 254/4885TUBB 196/4885TUBA3C 124/4885 |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | MCTS1, CA14, TTL | TUBB4A 103/4885TUBB 56/4885TUBA3C 142/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | TUBB4A 95/4885TUBB 40/4885TUBA3C 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.